Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer research from University of Texas described
September 18th, 2008
According to recent research from the United States, "Phosphatidylinositol 3-kinase (Pl3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopybased sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to P13K inhibition in vitro and on outcome after adjuvant tamoxifen." "PIK3CA mutations were more common in hormone receptor-positive (34.5%) and HER2positive (22.7%) than in basal-like tumors (8.3%). AKT-1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone...
Source: Women's Health Weekly (2008-09-18)
|
